GMX Reliance Gen.

RNS Number:6119M
GeneMedix PLC
28 January 2008



FOR IMMEDIATE RELEASE 28th January 2008


                                 GeneMedix plc

                       Changes to the Board of Directors


GeneMedix plc (the "Company"), the AIM listed biopharmaceutical company, which
is part of the Reliance Life Sciences Group ("RLS"), confirms that, subsequent
to a Board meeting held on 24 January 2008, the following changes to the Board
have been undertaken with immediate effect:


Non-Executive Chairman - Dr Ramesh Mashelkar

Dr. Ramesh Mashelkar has formally accepted the post of Non-Executive Chairman.
Dr. Mashelkar, aged 64, is an eminent scientist with an outstanding academic
record and has held a number of high profile positions in the field of science
and technology. He is currently President of Global Research Alliance, a network
of publicly funded research and development institutes from Asia Pacific, Europe
and the USA representing over 60,000 scientists and the President of the Indian
National Science Academy (INSA). Prior to this he served as Director General of
the Council of Scientific and Industrial Research (CSIR). Dr Mashelkar has 26
honorary doctorates, and is only the third Indian engineer in over 100 years to
have been elected a Fellow of the Royal Society (FRS) in London.


Dr. Mashelkar replaces Dr Kim Tan, a co-founder of GeneMedix, who steps down
from the Board. Dr. Kim Tan leaves the Board at an exciting point in its
development and the Board expresses sincere gratitude for his invaluable
contribution and guidance in bringing GeneMedix to its current stage and wishes
him well for the future.


Chief Executive Officer - Mr Vinay Ranade

Vinay Ranade has taken over as CEO of the Company from 1 January 2008 and is
based at the Company's offices in Ireland. Vinay Ranade, aged 40, is a Chartered
Accountant and a management graduate by qualification and has over 17 years of
experience in various fields including investment banking, finance and
commercial functions, business and operations. He has been a core team member in
developing the biotechnology initiatives at Reliance Life Sciences since 2001.
He was associated with the Company during the acquisition process by RLS from
December 2005 and has also been part of the integration team since that date.

These changes were previously advised in notifications on 6 July and 12 December
2007.

The Company also confirms that neither of the new directors has ever:

(i)   had any unspent convictions in relation to indictable offences; or

(ii)  been bankrupt or the subject of a voluntary arrangement, or had a receiver
      appointed to any of his assets; or

(iii) been a director of any company which, while a director with an executive
      function or within 12 months after ceasing to be a director with an 
      executive function, had a receiver appointed or been into compulsory 
      liquidation, creditors voluntary liquidation, administration or company 
      voluntary arrangements, or made any composition or arrangements with its 
      creditors generally or with any class of its creditors; or

(iv)  been a partner of any partnership, which while he was a partner or within
      12 months after he ceased to be a partner, went into compulsory liquidation,
      administration or partnership voluntary arrangement, or had a receiver 
      appointed to any partnership asset; or

(v)   had any public criticism by statutory or regulatory authorities (including
      recognised professional bodies); or

(vi)  been disqualified by a court from acting as a director or from acting in
      the management or conduct of affairs of any company.

The Company further confirms that neither of the new directors holds any shares
in the Company.

The list of directorships held by the new directors both currently and at any
time in the previous five years is as follows:

Dr. Ramesh Mashelkar

*  Reliance Industries Ltd., India
*  Tata Motors Ltd., India
*  ICICI Knowledge Park, India


Mr. Vinay Ranade

*  GeneMedix Ireland Ltd., Ireland
*  Reliance Life Sciences Pvt. Ltd., India
*  Reliance Biofuels Pvt. Ltd., India
*  Reliance Diagnostics Pvt. Ltd., India
*  Reliance Health and Technologies Pvt. Ltd., India
*  Biometrix Marketing Pvt. Ltd., India
*  Reliance Life Sciences Inc., USA


ENQUIRIES:

GeneMedix plc                                            Tel: +353 57 932 3572
Vinay Ranade, Chief Executive Officer

Deloitte Corporate Finance                               Tel: 020 7936 3000
Jonathan Hinton, John Ball

Bankside Consultants                                     Tel: 020 7367 8888
Michael Padley, Susan Scott







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOAUVVNRWVRAUAR

Reliance Genemedix (LSE:GMX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Reliance Genemedix (LSE:GMX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025